A key U.S. government report on mental health, substance use and addiction shows continued improvements in several metrics, especially among young people.

Simtriyo’s mechanism combines norepinephrine/dopamine augmentation with serotonin modulation, expanding beyond traditional stimulant and selective nonstimulant approaches for heterogeneous ADHD ...

Supported by four phase 3 clinical trials, Simtriyo offers a novel triple-reuptake inhibition mechanism for managing core ADHD symptoms across pediatric and adult populations.

Understood reports that the FDA has approved Simtriyo, a new ADHD medication targeting dopamine, norepinephrine, and ...

The Substance Abuse and Mental Health Services Administration July 27 released results from its latest national survey on ...

Federal authorities convicted a telehealth company founder and clinical president for illegal stimulant prescription ...

HealthDay News — Athletes with attention-deficit/hyperactivity disorder (ADHD) may be more susceptible to sport-related concussion (SRC) and have a longer recovery period, according to a review ...

Otsuka Pharmaceutical plans to launch Simtriyo—the first norepinephrine, dopamine, serotonin reuptake inhibitor—later this year following scheduling by the U.S. Drug Enforcement Agency. The FDA has ...

The FDA has approved Otsuka Pharmaceutical’s once-daily extended-release capsule Simtriyo (centanafadine) f | Approval of the ...

New research reveals ADHD isn't one-size-fits-all — covering social media's specific role, why medication rarely 'stops ...

Ads on Instagram, TikTok, and YouTube are painting prescription stimulants in a negative light while promoting supplements ...

Triple reuptake inhibitor centanafadine is indicated for patients ages 6 years and older ...